Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil.
- Author:
Jae Joon HAN
1
;
Sun Kyung BAEK
;
Jae Jin LEE
;
Gou Young KIM
;
Si Young KIM
;
Suk Hwan LEE
Author Information
1. Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea. wkiki@naver.com
- Publication Type:In Vitro ; Original Article
- Keywords:
Colorectal neoplasms;
ERCC1;
Fluorouracil;
Oxaliplatin;
TRAP1
- MeSH:
Colorectal Neoplasms*;
DNA Repair;
Drug Resistance, Multiple;
Drug Therapy;
Fluorouracil;
Heat-Shock Proteins;
Humans;
Immunohistochemistry;
Multivariate Analysis;
Tumor Necrosis Factor-alpha
- From:Cancer Research and Treatment
2014;46(1):55-64
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The novel heat shock protein tumor necrosis factor receptor-associated protein 1 (TRAP1) is associated with multidrug resistance in colorectal cancer (CRC) cells in vitro. Excision repair cross-complementation group 1 (ERCC1) expression levels in tumor tissues also predict clinical outcomes in metastatic CRC patients receiving combination oxaliplatin and 5-fluorouracil treatment. We investigated whether TRAP1 and ERCC1 protein expression by immunohistochemistry predict clinical outcomes in CRC patients. MATERIALS AND METHODS: The study population consisted of 56 patients with metastatic CRC who received first-line oxaliplatin/5-fluorouracil therapy. Clinical response and overall survival (OS) by levels of the markers TRAP1 and ERCC1 were evaluated. RESULTS: The rates of TRAP1 and ERCC1 expression were 21% and 52%, respectively. Patients negative for ERCC1 expression showed a tendency to respond to chemotherapy (p=0.066). Median OS was significantly longer in patients negative for TRAP1 than those positive for TRAP1 (p=0.023). Patients negative for ERCC1 expression also had a better OS than those positive for ERCC1 (p=0.021). The median OS was 30.9 months for patients negative for TRAP1 and ERCC1 compared to 13.2 months for those positive for TRAP1 and/or positive for ERCC1 expression (p=0.006). The combination of TRAP1 and ERCC1 expression was significantly associated with the response to chemotherapy (p=0.046) and independently predicted median OS in multivariate analysis (hazard ratio, 2.98; 95% confidence interval, 1.18 to 7.49). CONCLUSION: The present study demonstrates that the combination of TRAP1 and ERCC1 expression predicts the survival of metastatic CRC patients who were treated with oxaliplatin/5-fluorouracil.
